Evaluation of Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Using EuroFlow Approaches

Background & Aims. Evaluation of the minimal residual disease (MRD) at different stages of chemotherapy is one of key prognostic factors and a factor of stratification of patients into risk groups in acute lymphoblastic leukemia (ALL). The MRD detection on Day 15 and at later stages is based on...

Full description

Saved in:
Bibliographic Details
Main Authors: OA Beznos, LYu Grivtsova, AV Popa, MA Shervashidze, IN Serebryakova, OYu Baranova, EA Osmanov, NN Tupitsyn
Format: Article
Language:Russian
Published: Practical Medicine Publishing House 2017-04-01
Series:Клиническая онкогематология
Subjects:
Online Access:http://bloodjournal.ru/wp-content/uploads/2017/03/4.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849765747596722176
author OA Beznos
LYu Grivtsova
AV Popa
MA Shervashidze
IN Serebryakova
OYu Baranova
EA Osmanov
NN Tupitsyn
author_facet OA Beznos
LYu Grivtsova
AV Popa
MA Shervashidze
IN Serebryakova
OYu Baranova
EA Osmanov
NN Tupitsyn
author_sort OA Beznos
collection DOAJ
description Background & Aims. Evaluation of the minimal residual disease (MRD) at different stages of chemotherapy is one of key prognostic factors and a factor of stratification of patients into risk groups in acute lymphoblastic leukemia (ALL). The MRD detection on Day 15 and at later stages is based on identifying blast cells with a leukemia-associated immune phenotype. The aim is to assess the potential of 8-color standardized EuroFlow panels and to detect individual criteria for MRD monitoring during primary diagnosis. Materials & Methods. The analysis included data on the primary immune phenotype and MRD assessment during chemotherapy in 10 adults and 35 children with a confirmed diagnosis of B-cell precursors ALL. Results. The ALL phenotype characteristics at the stage of primary diagnosis permit to make the most complete description of the of 8-color standardized EuroFlow panels. This gives an opportunity to select the most informative antigen combinations for further MRD monitoring. Combinations with CD58/CD38, CD81/СD9 antigen expression, as well as assessment of pan-myeloid CD13, CD33 antigen co-expression may be recommended as the most frequent aberrant immune phenotypes of blast cells in ALL. As for B-lineage progenitor cells in children on Day 15 of the induction therapy, a detection of TdT+ сyCD22+ cell population is necessary in addition to the quantification of CD10+ and/or CD34+ В-lineage progenitor cells. Conclusion. Therefore, the 8-color standardized EuroFlow panels permit not only to characterize the primary ALL immune phenotype in details, but may also be widely used for MRD evaluation at all stages of chemotherapy.
format Article
id doaj-art-c6baff1459cf480fb5ca45932b6e2eec
institution DOAJ
issn 1997-6933
2500-2139
language Russian
publishDate 2017-04-01
publisher Practical Medicine Publishing House
record_format Article
series Клиническая онкогематология
spelling doaj-art-c6baff1459cf480fb5ca45932b6e2eec2025-08-20T03:04:46ZrusPractical Medicine Publishing HouseКлиническая онкогематология1997-69332500-21392017-04-0110215816810.21320/2500-2139-2017-10-2-158-168Evaluation of Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Using EuroFlow ApproachesOA Beznos0LYu Grivtsova1AV Popa2MA Shervashidze3IN Serebryakova4OYu Baranova5EA Osmanov6NN Tupitsyn7NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478Background & Aims. Evaluation of the minimal residual disease (MRD) at different stages of chemotherapy is one of key prognostic factors and a factor of stratification of patients into risk groups in acute lymphoblastic leukemia (ALL). The MRD detection on Day 15 and at later stages is based on identifying blast cells with a leukemia-associated immune phenotype. The aim is to assess the potential of 8-color standardized EuroFlow panels and to detect individual criteria for MRD monitoring during primary diagnosis. Materials & Methods. The analysis included data on the primary immune phenotype and MRD assessment during chemotherapy in 10 adults and 35 children with a confirmed diagnosis of B-cell precursors ALL. Results. The ALL phenotype characteristics at the stage of primary diagnosis permit to make the most complete description of the of 8-color standardized EuroFlow panels. This gives an opportunity to select the most informative antigen combinations for further MRD monitoring. Combinations with CD58/CD38, CD81/СD9 antigen expression, as well as assessment of pan-myeloid CD13, CD33 antigen co-expression may be recommended as the most frequent aberrant immune phenotypes of blast cells in ALL. As for B-lineage progenitor cells in children on Day 15 of the induction therapy, a detection of TdT+ сyCD22+ cell population is necessary in addition to the quantification of CD10+ and/or CD34+ В-lineage progenitor cells. Conclusion. Therefore, the 8-color standardized EuroFlow panels permit not only to characterize the primary ALL immune phenotype in details, but may also be widely used for MRD evaluation at all stages of chemotherapy.http://bloodjournal.ru/wp-content/uploads/2017/03/4.pdfB-lineage acute lymphoblastic leukemiamulticolor flow cytometryminimal residual disease
spellingShingle OA Beznos
LYu Grivtsova
AV Popa
MA Shervashidze
IN Serebryakova
OYu Baranova
EA Osmanov
NN Tupitsyn
Evaluation of Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Using EuroFlow Approaches
Клиническая онкогематология
B-lineage acute lymphoblastic leukemia
multicolor flow cytometry
minimal residual disease
title Evaluation of Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Using EuroFlow Approaches
title_full Evaluation of Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Using EuroFlow Approaches
title_fullStr Evaluation of Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Using EuroFlow Approaches
title_full_unstemmed Evaluation of Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Using EuroFlow Approaches
title_short Evaluation of Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Using EuroFlow Approaches
title_sort evaluation of minimal residual disease in b lineage acute lymphoblastic leukemia using euroflow approaches
topic B-lineage acute lymphoblastic leukemia
multicolor flow cytometry
minimal residual disease
url http://bloodjournal.ru/wp-content/uploads/2017/03/4.pdf
work_keys_str_mv AT oabeznos evaluationofminimalresidualdiseaseinblineageacutelymphoblasticleukemiausingeuroflowapproaches
AT lyugrivtsova evaluationofminimalresidualdiseaseinblineageacutelymphoblasticleukemiausingeuroflowapproaches
AT avpopa evaluationofminimalresidualdiseaseinblineageacutelymphoblasticleukemiausingeuroflowapproaches
AT mashervashidze evaluationofminimalresidualdiseaseinblineageacutelymphoblasticleukemiausingeuroflowapproaches
AT inserebryakova evaluationofminimalresidualdiseaseinblineageacutelymphoblasticleukemiausingeuroflowapproaches
AT oyubaranova evaluationofminimalresidualdiseaseinblineageacutelymphoblasticleukemiausingeuroflowapproaches
AT eaosmanov evaluationofminimalresidualdiseaseinblineageacutelymphoblasticleukemiausingeuroflowapproaches
AT nntupitsyn evaluationofminimalresidualdiseaseinblineageacutelymphoblasticleukemiausingeuroflowapproaches